201 results about "Positive contrast" patented technology

The invention relates to a sesterterpane as formula (1) and relative medical drug or solvent, and relative drug compound, which can reduce hepatitis B surface antigen and restrain hepatitis B HBVDNA copy activity. Wherein, said invention has strong restrain on hepatitis B surface antigen (HBsAg) generated by HepG2.2.15 cell and the copy of hepatitis B deoxyribonucleic acid (HBV-DNA), while it restrain ability is higher than positive contrast difuradin; and the copy restrain activity at large amount (100 mug/mL) and middle amount (20 mug/mL) on the hepatitis B HBV-DNA are both higher then difuradin.

The invention discloses a male multi-tumor marker detection protein chip and a kit thereof. The chip comprises a substrate, protein markers distributed in an array type and point coatings of contrasts, wherein the substrate is a glass substrate or a film substrate; and the tumor markers and the point coatings of the contrasts are seven protein markers of AFP, CEA, NSE, CYFRA21-1, CA19-9, tPSA and SCC-ag, a positive contrast and a negative contrast which are uniformly distributed and latticed on the substrate. A reaction result of various indexes can be obtained only through one reaction by utilizing the protein chip, and the following tumors can be simultaneously screened: primary liver cancer, prostatic cancer, pancreatic cancer, lung cancer, esophageal cancer, gastric cancer and colorectal cancer. The invention is particularly suitable for the general examination of malignant tumors of male asymptomatic groups and high risk groups.

The invention belongs to the field of nucleic acid detection and discloses a method for semi-quantitatively detecting pathogenic nucleic acid by adding internal control nucleic acid. Corresponding internal control is added in the whole process of extracting and amplifying target nucleic acid and testing by using a test paper, so that the internal control and a target segment are parallelly operated, and the semi-quantitative detection is performed finally through color development and intensity contrast of three strips, namely a detection line, an internal control line and a quality control line on the test paper. In the method, in the whole process of processing the target nucleic acid, the corresponding internal control is taken as a positive contrast, and false negative results due to links such as extraction, amplification or sample application errors are avoided in the processing of detecting by using the test paper. Meanwhile, by comparing color development intensity of the internal control line and a sample line and introducing the semi-quantitative function on the basis of the qualitative function of the immunochromatographic test paper to estimate the copy number of tested samples, the detection results are more detailed, accurate and reliable. The method has the advantages of convenient and quick operation and capacity of meeting the actual clinical requirement.

The invention discloses a kit for detecting pig pseudorabies virus antibodies and a block enzyme-linked immuno sorbent assay (ELISA) method. The kit for detecting pig pseudorabies virus antibodies comprises pig pseudorabies virus monoclonal antibodies which are labelled by horseradish peroxidase, wherein the pig pseudorabies virus monoclonal antibodies are monoclonal antibodies obtained by pig pseudorabies viruses as immunogens and the pig pseudorabies viruses are pseudorabies virus strain Ea. The kit for detecting pig pseudorabies virus antibodies also comprises an enzyme label plate, a sample diluent, negative and positive contrasts, a coloured solution, a washing solution, and a stopping solution. The block ELISA method comprises the following steps of 1, taking out a detection plate pre-coated with virus antigens from the kit for detecting pig pseudorabies virus antibodies, adding diluted blood serum needing to be detected into the detection plate pre-coated with the virus antigens, and simultaneously, setting negative and positive contrast apertures, 2, shaking up the diluted blood serum in the negative and the positive contrast apertures, shaking off a solution in the negative and the positive contrast apertures, and washing the detection plate by the washing solution, and 3, adding the pig pseudorabies virus monoclonal antibodies labelled by horseradish peroxidase into the negative and the positive contrast apertures, washing, adding the colored solution into the negative and the positive contrast apertures to carry out room-temperature coloration in the dark, adding the stopping solution into the negative and the positive contrast apertures, and determining OD630nm values of the negative and the positive contrast apertures by an ELISA apparatus. The block ELISA method has the advantages of good singularity, high sensitivity, short detection time, and high accuracy because of utilization of an S/N ratio method in result determination.

The invention relates to application of dimethyl dehydrated silybin in preparing medicaments for treating virus hepatitis B, in particular to the application of 7 and 20-position methyl substituted dehydrated silybin or pharmaceutically acceptable salts thereof in preparing medicaments for removing HBsAG and HBsAg and medicaments for inhibiting HBV DNA replication. The dehydrated silybin has remarkably HBsAg and HBeAg inhibiting activity, wherein the strength for removing the HBsAg and the HBeAg at the concentration of 20 milligram/milliliter is 88.9 percent and 84.1 percent respectively, which are 5.5 times and 5.0 times that of a positive contrast medicament. More importantly, the dehydrated silybin shows the HBV DNA inhibition ratio of about 99.6 percent at the concentration of 20 milligram/milliliter, the activity exceeds lamivudine by 23 percent, which is 2.6 times that of interferon. Therefore, favonolignan or pharmaceutically acceptable salts thereof can be predictably used for preparing the non-nucleoside reverse transcriptase inhibitor medicaments for removing the HBsAg and HBeAg, inhibiting HBV DNA replication and treating hepatitis B virus infection diseases.

The device comprises: a sample application zone, a reagent zone, a detection zone with positive and negative contrast zones and the combination zone for detected target, and a reagent strip. Wherein, the positive contrast zone comprises one or more material to show the first color on dried condition and the second color when on wet condition. If there is detected target in sample, the interactive action of the combination zone and contrast zone forms the legible symbols.

The invention discloses a rapid diagnostic kit based on a loop-mediated isothermal amplification technique for hepatitis A virus genes and a detection method thereof. The kit comprises two pairs of primers, Bst DNA polymerase, revertase, an RNase inhibitor, a stabilizing solution, a reaction solution, a chromogenic solution and a positive contrast solution, wherein the nucleotide sequences of thetwo pairs of primers are shown in SEQ ID NO: 1-4; and the eight solutions are respectively contained in containers. The kit and the detection method can detect the hepatitis A virus with high efficiency and high specificity, are based on the loop-mediated isothermal amplification technique, apply six segments, four primers and one constant temperature to complete an amplification reaction within less than one hour, and have the advantages of low detection cost, short time consumption, high yield, high specificity, significant chromogenic difference between a positive result and a negative result, high authentication rate, distinctness and reliability.

Contrast agents incorporating super-paramagnetic iron-oxide (SPIO) nanoparticles have shown promise as a means to visualize labeled cells using MRI. Labeled cells cause significant signal dephasing due to the magnetic field inhomogeneity induced in water molecules near the cell. With the resulting signal void as the means for detection, the particles are behaving as a negative contrast agent, which can suffer from partial-volume effects. Disclosed is a new method for imaging labeled cells with positive contrast. Spectrally-selective RF pulses are used to excite and refocus the off-resonance water surrounding the labeled cells so that only the fluid and tissue immediately adjacent to the labeled cells are visible in the image. Phantom, in vitro, and in vivo experiments show the feasibility of the new method. A significant linear correlation (r=0.87, p<0.005) between the estimated number of cells and the signal has been observed.

The invention provides an immunity diagnosis test kit for detecting II-type dengue virus antigen, which comprises a porous reaction plate covering monoclonal antibody DV2-M6, a sample treatment liquid, a monoclonal antibody DV2-M15 marked with a label, a positive contrast, a negative contrast, a concentration washing liquid, a develop liquid and a termination liquid, wherein the monoclonal antibodies DV2-M6 and DV2-M14 of the test kit can be specifically combined with NS1 protein of II-type dengue virus, without cross reaction with other three kinds of serotype dengue viruses NS1 and respectively combined with different antigen points of NS1, while the check sensitivity of NS1 protein of II-type dengue virus can reach 3ng/ml and the check sensitivity of culture supernatant of II-type dengue virus infection cell is 8 power of Pan-E dengue early elisa test kit, thereby improving the sensitivity of clinical serum sample check.

The invention measures the vertical component Hz of a magnetic field arising from natural sources (MT) simultaneously at a plurality of points (70) on the sea floor to determine places having a non-zero vertical component Hz indicative of an edge of a resistive body (structure) (40), in order to determine whether or not a sub-bottom geologic structure (20), known from marine seismic measurements, exhibits a resistivity contrast with the surrounding rocks, a positive contrast being interpreted as indicating hydrocarbon charge within the structure.

The invention discloses a Korean novel duck hepatitis viral antibody ELISA (Enzyme-Linked Immunosorbent Assay) detection kit. The detection kit contains an ELISA board coated by Korean novel duck hepatitis VP1 (Phenotypic Variance1) recombination protein, a sample diluent, concentrated washing liquid, an enzyme conjugate working solution, a chromogenic reagent (A), a chromogenic reagent (B), a stopping solution, a positive contrast solution and a negative contrast solution. The VP1 recombination protein is obtained by using the following method: using Korean novel duck hepatitis viruses as a material, augmenting and cloning the VP1 gene through an RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction) method to obtain recombinant expression plasmid pMD (physical medium dependent)-VP1; then, directionally inserting to an expression vector pET-32a (+) and screening to obtain recombinant expression plasmid pET-32a(+)-VP1; and inducing, expressing and purifying by ITPG (Isopropyl beta-D-Thiogalactopyranoside) to obtain VP1 recombination protein. The detection kit is used for detecting the Korean novel duck hepatitis and has strong specificity, high sensitivity, simplicity of operation, easiness of popularization and application in a large-area range and wide market prospects.

The invention relates to a composite kit for detecting avian influenzas and Newcastle disease viruses and a detection method, characterized in that the kit comprises a lysis solution, an RT-PCR buffer solution, primers and a probe mixture solution, particularly a primer and a probe sequenc for detecting various subtype avian influenzas viruses, a primer and a probe sequenc for detecting Newcastle medium and strong viruses, enzyme mixture, DEPC water and negative and positive contrasts. The detection method comprises the following steps of: carrying out an RT-PCR reaction and judging a quality control standard and results. The invention has the advantages of high sensitivity, good specificity and simple operation. The process from processing samples to getting a result only needs 4 hours. The invention overcomes the defects of single fluorescence and realizes the aim of simultaneously detecting two viruses by one real-time fluorescent quantification PCR (Polymerase Chain Reaction) reaction.

The invention belongs to the field of inspection and quarantine technology. Specifically, the invention is a nucleic acid detection reagent kit for synchronous discriminating and diagnosing avian influenza virus and newcastle disease virus. The detection reagents of the reagent kit include extraction reagent for extracting virus by silicon gel absorption column method, detection amplification reagent for detecting nucleic acid by RT-PCR Taq Man fluorescent probe method, and pretreatment liquid for solid tissue specimen for extracting virus RNA. Further, the invention employs in vitro transcription RNA as a positive contrast of the reagent kit. The reagent kit can rapidly and synchronously discriminate and diagnose avian influenza virus and newcastle disease virus which are highly infectious among avian plagues and have similar symptom, determine current major prevalent subtypes, such as H5, H7, H9, etc., and discriminate whether a infection source is an avian influenza having high pathogenicity, non-pathogenic avian influenza or mildly pathogenic avian influenza to human. The reagent kit is suitable for livestock and veterinarian station, import and export inspection and quarantine bureau, as well as other laboratories, and can be used for large-scale detection of influenza and epidemic surveillance.

A hepatitis c virus antigen-antibody joint detection reagent box is characterized by comprising a calibrator(1), a double-marker enzyme conjugate (2), a negative and positive contrast (3), light-emitting liquid (4) and a micropore coated plate (5), wherein the light-emitting liquid contains light-emitting liquid 1 and light-emitting liquid 2, the light-emitting liquid 1 contains luminal 0.7 g/L, cinnamic acid 0.9 g/L, 4-iodophenylboronic acid 0.2 g/L, iodobiphenol 0.25 g/L, dimethylformamide 25 ml/L, polyving akohol 5 g/L, polyvinylpyrrolidone 8 g/L, polyethylene glycol 600 3 g/L, ethylenediamine tetraacetic acid 4 g/L, gentamicin sulfate 1600 thousands/L, urea peroxide 0.4 g/L, and pH 9.0 Tris buffer solution 0.1 mol/L. The light-emitting liquid 2 contains acridinium ester derivative 0.1 mg/ml, polyethylene glycol 600 3 g/L and 0.1 mol/L of pH 9.0 Tris buffer solution containing 0.1% of TWEEN-20. The invention further discloses a preparation method and a using method of the reagent box. The hepatitis c virus antigen-antibody joint detection reagent box has the advantages of being quick in reaction and low in cost.

The invention discloses a color protein chip which substrate is BCIP/NBT. The invention is composed of a substrate, an array, 12 antigens coated on the array, negative contrast, positive contrast and blank contrast, wherein the substrate is a glass slide decorated by APES, the kinds and point sample densities of the 12 antigens are 520ug/ml ANA, 465ug/ml Ro-60, 530ug/ml La/SSb, 530ug/ml Jo-1, 525ug/ml Scl-70, 520ug/ml Sm, 615ug/ml Ro-52/SSa, 340ug/ml RF, 465ug/ml CCP, 410ug/ml u1RNP, 490ug/ml CENP-B, 580ug/ml dsDNA. The invention uses the alkali phosphatase coloring method whose substrate is BCIP/NBT as the final check signal of protein chip to be widely used for self antibody check, while the check sensitivity has higher coincidence rate than prior art, with reduced check cost and time. The invention can be used in clinical check, sanitary supervision, regular sanitary supervision and scientific research or the like.

The invention discloses a positive plasmid molecule pBI121-Screening and application thereof and relates to the technical field of safety supervision and screening detection of transgenic crops in the transgenic safety field. The base sequence of the pBI121-Screening is as shown in SEQ NO.1. serving as both a positive contrast and a quality control sample, pBI121-Screening disclosed by the invention can be respectively used in general PCR and real-time fluorescence PCR screening detection of transgenic components of six transgenic crop samples, namely paddy rice, rapes, soybeans, corns, cotton and wheat. The pBI121-Screening disclosed by the invention can be used for solving the technical problem that the lack of a positive contrast or a standard sample in the screening detection of the transgenic crops, and prevents the problem that a plurality of positive contrasts are arranged for a plurality of detection targets in the screening detection, thus reducing the labor cost and economic cost for preparing the plurality of positive contrasts.

The invention provides a detection probe for an SNP (Single Nucleotide Polymorphism) of a human CYP2C19 gene. A detection primer consists of a specific upstream and downstream primer pair of the gene and a specific Taqman double fluorescent probe which are respectively used for correspondingly detecting SNPs at CYP2C19*2, CYP2C19*3 and CYP2C19*17 sites. The detection probe has the characteristics of quick detection and high specificity; furthermore, the detection method is simple; positive contrast and negative contrast which are necessary to conventional fluorescent quantitation PCR are eliminated, so that the operation steps and the experimental cost are reduced; the subsequent clinical treatment strategy can be guided more quickly and better.

The invention provides a camptothecin-site 20 norcantharidate derivative with a structural formula as shown in I which is described in the specification, and a preparation method and antineoplastic application thereof. Results of activity test prove that the camptothecin-site 20 norcantharidate derivative as shown in I is an appropriate candidate antineoplastic drug, especially a candidate drug for resisting liver cancers, stomach cancers and colorectal cancers. Compared with positive contrast drugs, i.e., camptothecin and cantharidin, the camptothecin-site 20 norcantharidate derivative has improved water solubility and stability; and the camptothecin-site 20 norcantharidate derivative is sensitive to acid and can be easily hydrolyzed. Moreover, the preparation method for the camptothecin-site 20 norcantharidate derivative employs easily available raw materials, has high yield and is easy to operate and implement.

The invention discloses an oligonucleotide chip capable of detecting five enteroviruses simultaneously and an application thereof. The chip comprises a substrate, probes of pathogens of five enteroviruses coated on the substrate, negative contrast, positive contrast and blank contrast, wherein the probes of pathogens are five 54-70mer of HAV-P, ROV-P, NOV-P, ASV-P and ADV-PV1 probes. The chip of the invention adopts multiple PCR to amplify a plurality of target sequences of pathogens simultaneously and uses the downstream primer Tamara labeling method to perform fluorescence labeling to PCR product, the labeled PCR product is hybridized with the chip to realize the accurate detection of pathogens, the detection sensitivity is equal to that of PCR and the specificity is high. The detectionefficiency and accuracy are obviously shortened. The technology system of the invention is applicable to fields such as sea water and marine life specimens monitoring, food hygiene surveillance, customs quarantine, related clinical detection and the like.

The invention provides a method for detecting canine rabies virus antibody (IgG) and a detection kit. The kit is composed of a coated plate and a reagent reaction system, and comprises a rabies virus antigen-coated reaction plate, a standard substance, positive contrast serum, a washing lotion (20X), a sample weak solution, an enzyme-marked combination substance, a developer A, a developer B and a stopping solution. The method is characterized in that the method uses an ELISA method to determine that the content of the canine rabies virus antibody (IgG) reaches a absorbance corresponding to a protective level by detecting the standard substance of the kit, and by compared the absorbance of the sample to be detected with the absorbance of the standard substance, the content of the canine rabies virus antibody (IgG) contained in the sample to be detected is judged whether to reach an immunization protective level. The method and the kit can simultaneously detect a lot of samples, and a detection result is remarkably with a result by a neutralization experiment, has high accuracy degree, is suitable for monitoring an immunization inoculation effect and determining an individual immunization state, and can be used for investigating animal eqpidemic diseases.

The present invention relates to gene determining technology and is especially CpG insular methlation test reagent kit and its application for diagnosing tumor and screening demethylation medicine. The reagent kit includes primer, medicine for extracting template DNA, medicine for modifying genome, medicine for purifying DNA, specific MSP-PCR reaction system and negative and positive contrast samples. The present invention utilizes human gene sequences and designs primer based on base mismatch principle, and different gene primer is selected to constitute different reagent kit for detecting different diseases. The present invention may be used widely in the diagnosis of cancer and the screening of relevant medicine.